Spread awareness by sharing and learning more: Post the social media graphic, Listen to past conference sessions, and this webinar. Find these and other opportunities here: Caregiver Health and Wellness section.
In this webinar, Dr. Elizabeth Griffiths discusses research most relevant to patients reported over the past year on the biology and treatment on MDS and secondary AML. These studies were presented at the American Society of Hematology (ASH) 2021 meeting in Atlanta, GA. Research findings are explained along with the potential impact of this research on understanding and treating MDS and AML. This is an advanced scientific presentation.
Key Points
Structural racism (SR) assessed by census tract variables accounts for nearly all Black-white and Hispanic-white disparity in AML survival.
Structural Racism is a stronger mediator of survival disparities than molecular features, co-morbidities, healthcare access and treatment.
Abstract
Background
Despite widespread use, little is known about how adolescents and young adults (AYA) with cancer use social media (SM). This research characterized use and self-reported SM experiences among AYA with cancer.
Procedure
AYA, aged 12-26 years, receiving cancer care completed a mixed-methods survey regarding SM experiences. Clinical information was obtained from the electronic medical record. Data were analyzed with descriptive statistics, t tests, and qualitative content analysis.
Sabatolimab (MBG453) is a novel immuno-myeloid therapy that binds to TIM-3 on immune cells, facilitating antileukemic immune activation and phagocytic killing of leukemic cells. Sabatolimab also binds to TIM-3 on leukemic cells, potentially impeding self-renewal of LSCs via inhibition of TIM3-galectin-9.
Editor's note: Here's an update on Mychaela (see Stories of Hope)
Mychaela Lovelace is a sophomore at Michigan State University majoring in kinesiology in the College of Education, and is a scholar and mentor in the Dow STEM Scholars Program.
Zohra Nooruddin, MD received her medical degree from Ziauddin Medical University in Karachi, Pakistan, and attended Mount Sinai School of Medicine in Englewood, New Jersey for her residency. Dr. Nooruddin completed a fellowship in symptom control and palliative care at The University of Texas MD Anderson Cancer Center in Houston, and a fellowship in hematology-oncology at the University of Colorado Denver. She is board-certified in hospice and palliative medicine, and in hematology and oncology.
